← boardnext 2028-06-30
GANX
Gain Therapeutics, Inc.distress 3/10 · well-funded / low risk$1.82-1%today-56% from 52w high
Neurology 1
Lead: Parkinson's disease · est. market ~$6B (approx, global)
Revenue
pre-revenue
Liquidity
$20M
Runway
1.0 yrs
Shares 1y
+19%
Price & events
-12.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
+9.6%
1W
+2.8%
1M
-3.7%
3M
-11.2%
6M
+8.3%
1Y
+62.5%
2Y
-79.8%
5Y
-85.1%
All
Overview
- Market Cap
- $77.63M
- Enterprise Value
- $61.36M
- Volume
- 10.36K
- 52 Week Range
- $1.44 – $4.18
- Total Shares
- 42.65M
- Float Shares
- 41.65M
- Short %
- 8.66%
- % Held by Insiders
- 2.29%
- % Held by Institutions
- 19.24%
- RVOL
- 0.01x
- Beta
- 0.16
Pipeline stages · 2 programs
Low Dose GT-02287, High Dose GT-02287
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GT-02287
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06-30 Estimated 50% readout ~2028-08-14 | Phase 2 | Low Dose GT-02287, High Dose GT-02287 | Parkinson Disease | — | not yet recruiting |
| 2025-11-30 | Phase 1 | GT-02287 | Parkinson Disease | 20 | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 14
- 2H 2026Guided 55%trial initiationsecondaryPhase 2GT-02287 · Commencement of Phase 2 trialSEC 8-K
- 2H 2026Guided 55%readoutPhase 1GT-02287 · Phase 1b study extension analysisSEC 8-K
- September 2026Estimated 45%readoutPhase 1GT-02287 · Phase 1b extension (Part 2) anticipated to concludeSEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 2GT-02287 · Initiation of Phase 2a study in early Parkinson's disease patients.SEC 8-K
- 2026-06-29fda agreementGT-02287 · FDA authorized IND for GT-02287, allowing Phase 2 initiation in the US.SEC 8-K
- March 17-21, 2026conferencedata presentationsecondaryGT-04686 · Poster presentation of preclinical data for novel GCase modulator seriesSEC 8-K
- March 17-21, 2026conferencedata presentationsecondaryPhase 1GT-02287 · Oral presentation of Phase 1b clinical data at AD/PD 2026SEC 8-K
- 2026-03-05fda agreementGT-02287 · Data Monitoring Committee meeting concluded study should continue without changesSEC 8-K
- Q4 2025readoutPhase 1GT-02287 · Full results on 90-day biomarker evidence from all CSF and blood samplesSEC 8-K
- before end of 3Q25conferencedata presentationsecondaryPhase 1GT-02287 · Update on progress of extension of dosing period beyond 90 daysSEC 8-K
- by the end of the second quarter of 2025enrollment completesecondaryPhase 1GT-02287 · Phase 1b enrollment completion anticipatedSEC 8-K
- 2Q 2025readoutPhase 1GT-02287 · Interim analysis of Phase 1b clinical trial.SEC 8-K
- by the end of 1Q 2025enrollment completesecondaryPhase 1GT-02287 · Enrollment update for Phase 1b clinical trial.SEC 8-K
- December 23, 2024trial initiationsecondaryPhase 1GT-02287 · Initiated Phase 1b clinical trial in AustraliaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+296% upside) · 5 analysts
- 2026-07-01HC Wainwright & Co.Buy
- 2026-06-30BTIGBuy
- 2025-12-19HC Wainwright & Co.Buy
- 2025-10-15BTIGBuy
- 2025-10-13HC Wainwright & Co.Buy
- 2025-10-07Maxim GroupBuy
Competitors — Parkinson's disease
- DNLIDenali Therapeutics Inc.$3.6B · D2
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- ARVNARVINAS, INC.$525M · D1
- OVIDOvid Therapeutics Inc.$442M · D4
- IKTInhibikase Therapeutics, Inc.$289M · D4
- NAGENiagen Bioscience, Inc.$264M · D1
- VYGRVoyager Therapeutics, Inc.$184M · D4
- SERSerina Therapeutics, Inc.$33M · D6
- ALMSALUMIS INC.— · D4
Recent news
- 2026-07-17Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Canada
- 2026-07-17Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
- 2026-07-17Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
- 2026-07-17Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
- 2026-07-17Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
- 2026-07-17Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
- 2026-07-17Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.